A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin in Serum, Bronchial Washings and Lung Tissue Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Resection
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Azithromycin Cmax, Tmax, AUC72, (or AUClast for serum) and AUC24 from serum
predose, and at and at 2, 4, 8, 12, 16, 24, 48, and 72 hours postdose
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A0661145
NCT00644176
November 2004
April 2005
Name | Location |
---|